Europe's Med Tech Advantage Is Real, But Only If You Build It Right with Tatiana Lobanov-Rostovsky

<p>In this episode of the Crux of MedTech, Henry Norton is joined by Tatiana Lobanov-Rostovsky, Investor at Oxford Science Enterprises, the independent, billion-pound investment company built in partnership with the University of Oxford. With a background in neuroscience, Healthcare M&amp;A at Rothschild &amp; Co, and hands-on experience inside a biotech startup, Tatiana brings a rare view across the full lifecycle of medtech company building.</p><p><br></p><p>From the Europe vs US debate to why most companies fail not in R&amp;D but in commercial and what the best founders do differently from day one, this is a candid conversation about what it actually takes to build something the strategics will want.</p><p><br></p><p>Key Topics</p><p>Europe vs US: where medtech startups should build, raise, and scale</p><p>The Oxford Science Enterprises model, patient capital, EIR programmes, and venture building from university spinouts</p><p>How to spot the difference between a technology looking for a problem and a genuine clinical pull</p><p>Building for a strategic acquisition from day one, what the buyers actually want to see</p><p>Why commercial talent matters more than technical talent at the early stage</p><p>The EU/UK infrastructure gaps holding back medtech founders</p><p><br></p><p>Related Insights</p><p>Why hardware companies will outlast SaaS in a world of AI disruption and what that means for medtech investors</p><p>The NHS as a data advantage: how UK founders can use patient data to build globally competitive products</p><p>Structural heart and neurovascular as active investment themes and what&#39;s driving OSE&#39;s thesis building</p><p>Caristo Diagnostics and Ultromics as case studies in AI-powered cardiac diagnostics scaling for the US market</p><p><br></p><p>Core Challenges</p><p>The majority of medtech companies that reach FDA approval still fail in commercial, making go-to-market strategy as important as clinical validation.</p><p>European founders face a structural disadvantage in accessing the right commercial talent early enough, with risk aversion and brain drain compounding the problem.</p><p>Investors are paralysed by AI disruption uncertainty, but hardware-first, highly regulated sectors like medtech remain defensible, if founders and investors are willing to think long-term.</p><p><br></p><p>Tune in now to hear why the most valuable medtech companies are built from the commercial endpoint backwards and what the strategics are actually lo